AzTrials
AzTrials

Airway MorbidityNCT02923427

I-gel vs LMA Supreme in Laparoscopic Gynecological Surgery

A study testing Laryngeal mask Supreme Evaluation and i-gel Evaluation in people with Airway Morbidity and Anaesthesia, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To compare the effects of i-gel and Laryngeal mask airway Supreme (LMA-Supreme) on ventilation parameters and surgical view during Trendelenburg Position laparoscopic gynecological surgery in cases administered positive pressure ventilation without the use of neuromuscular agents. Read more about this study

Who is it for?
Ages 18 to 65 years, women only
Conditions the study is for
Airway Morbidity, Anaesthesia
What is being tested?
Laryngeal mask Supreme Evaluation and i-gel Evaluation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
112 participants
Where
1 siteTurkey (Türkiye)
Study dates
Nov 2015to Nov 2017
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • American Society of Anesthesiologists classification group I-II
  • between 18-65 years
  • undergoing elective laparoscopic gynecological surgery

Who cannot join

  • Those with any neck or upper respiratory tract pathology
  • Those at risk of gastric content regurgitation/aspiration (previous upper Gastrointestinal system surgery, known hiatus hernia, gastroesophageal reflux, history of peptic ulcers, full stomach, pregnancy)
  • Those with low pulmonary compliance or high airway resistance (chronic pulmonary diseases)
  • Obese patients (BMI >35)
  • Those with throat pain, dysphagia and dysphonia
  • Those with possible or previous difficult airway
Show all 9Show fewer
  • Those with operations planned for longer than 4 hours
  • Conversion to laparatomy
  • Neuromuscular blocking agent used

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation

    Izmir, 35340

Other trials in Turkey (Türkiye)

About this study

Official title: Comparison of I-gel and LMA Supreme Without Neuromuscular Blocker in Laparoscopic Gynecological Surgery

To compare the effects of i-gel and Laryngeal mask airway Supreme (LMA-Supreme) on ventilation parameters and surgical view during Trendelenburg Position laparoscopic gynecological surgery in cases administered positive pressure ventilation without the use of neuromuscular agents.

Read the detailed description

Prospective, randomized and double-blind study, aged from 18 to 65 years undergoing elective laparoscopic gynecological surgery.

The patients are randomly assigned to 2 groups:

  • Group 1: i-gel
  • Group 2: LMA- Supreme

Procedure:

The investigation protocol contains the following sections:

  1. Induction of anaesthesia. For preoperative sedation 0.02 mg/kg midazolam IV will be administered. 2 minutes of 0.2 µ/kg/min remifentanil and 6 mg kg st-1 propofol infusion, IV 1-2 mg kg-1 propofol . No muscle relaxant will be used for insertion of the airway device.
  2. Bispectral index values will be held between 40-60.Bispectral index values will be within this interval by increasing or decreasing propofol infusion by 1 mg/kg after additional bolus dose of propofol (1 mg/kg).
  3. Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations. All devices are deflated a lubricated prior to use. Once inserted, the cuff is be inflated with a manometer up to 60 cm H20 Data recorded: size of airway device, time an number of attempts.
  4. Anesthesia maintenance will be ensured by 50% O2/air with 0.1-0.4 µ kg/min-1 remifentanil and 50-150 µ kg/ min-1 (4-10 mg/kg/hr) propofol IV infusion
  5. Functionality of the gastric drainage channel of the airway device: passage of a 14 G size tube.
  6. Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and at 2 minutes after airway device insertion (T1), 10 minutes after insufflation (T2), before desufflation (T3), before removal of airway device (T4). The maximum pressure allowed is 40 cm H2O.
  7. Ventilatory mechanics and parameters and hemodynamic parameters are measured at baseline, and at T1, T2, T3 and T4.
  8. Perioperative complications: Cough, vomiting, laryngeal spasm, laryngeal Stridor, airway intervention requirements, hypoxia (SpO2 < 92%)
  9. Removal of the airway device: Presence of blood - 3 level grading (1:no blood; 2: trace amounts of blood; 3: clear amounts of blood). Complications: sore throat ( VAS:10-point scale), dysphonia (yes/no), dysphagia (yes/no).
Being tested
Laryngeal mask Supreme Evaluation, i-gel Evaluation
Keywords
laryngeal mask Supreme, i-gel, laparoscopic gynecological surgery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Laryngeal mask Supreme EvaluationDevice

    Evaluation of clinical performance in terms of Insertion, ventilation and complications

  • i-gel EvaluationDevice

    Evaluation of clinical performance in terms of Insertion,ventilation and complications

Study groups in NCT02923427
Study groupRoleWhat they receive
Laryngeal mask SupremeActive comparatorInsertion of the "Laryngeal mask Supreme" and evaluation of its clinical performance
Receives: Device: Laryngeal mask Supreme Evaluation
i-gelExperimentalInsertion of the "i-gel" and evaluation of its clinical performance
Receives: Device: i-gel Evaluation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Airway Seal Pressure Values

    This value is important as it indicates the feasibility of positive pressure ventilation and the degree of airway protection from supracuff soiling. It is also used in LMA studies as an index of successful placement.Airway pressures of ≈20 cm H2O are typically required in routine practice.

    Measured: At baseline and at 15, 30 and 60 minutes

Secondary outcomes (7)
  1. Visual Quality

    quality of surgical view will evaluate by the scala. quality of surgical view will be assessed with points from 1 to 4 by the surgeon blind to the airway device; (1:best, 4: worst).

    Measured: during pneumoperitoneum

  2. Gastric Tube Insertion

    Number of Participants According to Ease of Gastric Tube Insertion.Ease of passage of a gastric tube as: very easy, easy, difficult or very difficult.

    Measured: following airway device insertion up to 5 minutes

  3. Postoperative Pharyngolaryngeal Morbidity

    Sore throat evaluted by Visual Analogue Scale. The visual analog scale, also known as the graphic rating scale is a simple, valid and reliable subjective measure. Scores are ranked on a 10-cm line that stretches between two extremes - "no pain" and "worst pain". Total range provided"0 (no pain) to 10 (worst pain).

    Measured: postoperative first hour and 24th hour

  4. Sufficiency of Pneumoperitoneum

    Number of Participants with Sufficiency of Pneumoperitoneum. Sufficiency of pneumoperitoneum for the surgical procedure according to surgeon, described as sufficient or insufficient questionaire.

    Measured: baseline

  5. Mean Airway Pressure Values

    Mean airway pressure typically refers to the mean pressure applied during positive-pressure mechanical ventilation. Mean airway pressure correlates with alveolar ventilation, arterial oxygenation, hemodynamic performance, and barotrauma.

    Measured: At baseline and at 15, 30 and 60 minutes

  6. Dysphonia With Yes/no.

    We evaluated while a patient was talking with us that the patient has dysphonia or not .

    Measured: postoperative first hour and 24th hour

  7. Disphagia

    We asked the question that you have a pain while you were swallowing, yes or not.

    Measured: postoperative first hour and 24th hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2016 (estimated)
  2. Study startNov 2015
  3. Primary completionSep 2017
  4. Study completionNov 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
112 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02923427
Sponsor's protocol ID
266-SBKAEK
Status last verified
Oct 2020
First submitted
22 Sep 2016
Last updated
27 Oct 2020
Data monitoring committee
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Laryngeal mask Supreme Evaluation and i-gel Evaluation in people with Airway Morbidity and Anaesthesia, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Oct 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Airway Seal Pressure Values (time frame: At baseline and at 15, 30 and 60 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in